About the event

Held over a weekend, the event is structured around a series of exhibitions, workshops, and panel discussions. The exhibitions showcase a curated selection of photographs that tell compelling stories from various corners of the globe, each image accompanied by detailed narratives that provide context and deeper insight into the historical significance of the scenes depicted. These photographs are drawn from the archives of renowned photographers, as well as emerging talents, ensuring a blend of both classical and contemporary perspectives.

Cliff Palace, Colorado
Financial Fitness Check: Examining Jaguar Health Inc (JAGX)’s Key Ratios – DwinneX

Financial Fitness Check: Examining Jaguar Health Inc (JAGX)’s Key Ratios

Kiel Thompson

Those aspiring to outpace the market meticulously engage in the process of selecting individual stocks. Strategic choices can be instrumental in accelerating your wealth.

In the latest session, Jaguar Health Inc (NASDAQ: JAGX) closed at $1.28 up 3.23% from its previous closing price of $1.24. In other words, the price has increased by $3.23 from its previous closing price. On the day, 71163.0 shares were traded. JAGX stock price reached its highest trading level at $1.3301 during the session, while it also had its lowest trading level at $1.24.

Ratios:

For a deeper understanding of Jaguar Health Inc’s stock, let’s take a closer look at its various ratios. For the most recent quarter (mrq), Quick Ratio is recorded 0.52 and its Current Ratio is at 0.81. In the meantime, Its Debt-to-Equity ratio is 5.67 whereas as Long-Term Debt/Eq ratio is at 1.52.

Upgrades & Downgrades

In the most recent recommendation for this company, Cantor Fitzgerald on July 07, 2021, initiated with a Overweight rating and assigned the stock a target price of $5.

On July 11, 2017, Rodman & Renshaw started tracking the stock assigning a Buy rating and target price of $2.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, JAGX now has a Market Capitalization of 4781872 and an Enterprise Value of 34371872. For the stock, the TTM Price-to-Sale (P/S) ratio is 0.41 while its Price-to-Book (P/B) ratio in mrq is 1.50. Its current Enterprise Value per Revenue stands at 2.917 whereas that against EBITDA is -1.112.

Stock Price History:

The Beta on a monthly basis for JAGX is -0.07, which has changed by -0.9523077 over the last 52 weeks, in comparison to a change of 0.12159383 over the same period for the S&P500. Over the past 52 weeks, JAGX has reached a high of $33.25, while it has fallen to a 52-week low of $1.10. The 50-Day Moving Average of the stock is -33.00%, while the 200-Day Moving Average is calculated to be -74.67%.

Shares Statistics:

For the past three months, JAGX has traded an average of 151.04K shares per day and 149930 over the past ten days. A total of 3.69M shares are outstanding, with a floating share count of 2.63M. Insiders hold about 29.78% of the company’s shares, while institutions hold 2.55% stake in the company. Shares short for JAGX as of 1763078400 were 102632 with a Short Ratio of 0.68, compared to 1760486400 on 61045. Therefore, it implies a Short% of Shares Outstanding of 102632 and a Short% of Float of 3.45.

Earnings Estimates

Jaguar Health Inc (JAGX) is currently under the scrutiny of 1.0 analysts, each contributing to the ongoing evaluation of its stock.The consensus estimate for the next quarter is -$2.04, with high estimates of -$2.04 and low estimates of -$2.04.

Analysts are recommending an EPS of between -$23.81 and -$23.81 for the fiscal current year, implying an average EPS of -$23.81. EPS for the following year is -$5.68, with 1.0 analysts recommending between -$5.68 and -$5.68.

Revenue Estimates

A total of 1 analysts believe the company’s revenue will be $4.21M this quarter.It ranges from a high estimate of $4.21M to a low estimate of $4.21M. As of. The current estimate, Jaguar Health Inc’s year-ago sales were $3.51MFor the next quarter, 1 analysts are estimating revenue of $3.67M. There is a high estimate of $3.67M for the next quarter, whereas the lowest estimate is $3.67M.

A total of 1 analysts have provided revenue estimates for JAGX’s current fiscal year. The highest revenue estimate was $12.56M, while the lowest revenue estimate was $12.56M, resulting in an average revenue estimate of $12.56M. In the same quarter a year ago, actual revenue was $11.69MBased on 2 analysts’ estimates, the company’s revenue will be $26.55M in the next fiscal year. The high estimate is $34.87M and the low estimate is $18.23M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.